Star Therapeutics raises $200M to rebuild its pipeline after Vega and Electra exits

Star Therapeutics has closed a $200 million private financing, co-led by OrbiMed and Janus Henderson Investors, to move its preclinical programmes into the clinic and add new ones. The company announced the round on 23 October from South San Francisco.

Who put money in

Alongside the two leads, the syndicate includes Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, RA Capital Management, Redmile, Sofinnova Investments, Soleus Capital and an unnamed sovereign wealth fund. Vish Sridharan, assistant portfolio manager and research analyst at Janus Henderson, will join the board as an observer.

"We do not often invest in companies at this stage of development." Vish Sridharan, Janus Henderson Investors

That line is the interesting part. Crossover and public-market investors usually arrive later, once there is clinical data. Here they are backing a team rather than a lead asset.

Why the team gets the benefit of the doubt

Star's founder and CEO is Adam Rosenthal. According to the company, its team has invented four first-in-class therapies that are now in Phase 3 or on the market, including Enjaymo, the first approved drug for cold agglutinin disease. The release also lists four acquisitions in the team's track record: Vega Therapeutics, DICE Therapeutics, True North Therapeutics and iPierian.

The most recent exit was Vega. Incyte bought it in July 2026 in a deal worth up to $2 billion, taking with it latarcibart (VGA039), an antibody in Phase 3 for von Willebrand disease. A second spinout, Electra Therapeutics, listed on Nasdaq in September 2026.

A reset to early stage

With its most advanced assets gone, Star is effectively starting again. Axios Pro describes the round as resetting Star as an early-stage biotech, with the money going into its hematology and immunology pipeline. The company has not named the new programmes or said when the first will enter the clinic.

The model is a repeatable one: build programmes in house, spin them into focused companies, and sell or float them once they have value. Investors are now paying for the next turn of that cycle before any of it is visible.

The bigger picture

Star's round stands out against the year so far. BioPharma Dive's first-half tally found that about 76% of venture money went into rounds of $100 million or more, and that about two-thirds of rounds went to companies that already had a drug in human testing. EY's Ashwin Singhania told the outlet that seed rounds and money for first-time founders are harder to find than five years ago. Big money for a preclinical portfolio is rare, and here it has gone to a team with a record of exits.